Literature DB >> 8586703

Quantitation of human immunodeficiency virus type 1 DNA by two PCR procedures coupled with enzyme-linked oligosorbent assay.

F Mallet1, C Hebrard, J M Livrozet, O Lees, F Tron, J L Touraine, B Mandrand.   

Abstract

Two quantitative PCR methods with our nonisotopic enzyme-linked oligosorbent assay (ELOSA) in microtiter plate format were developed for quantitation of human immunodeficiency virus type 1 (HIV-1). Quantitative competitive PCR (QC-PCR) was based on the coamplification of the wild-type nef region with a mimic competitive nef gene template carrying mutations in the capture region. Correlation of wild-type HIV-1 nef DNA to mimic template copy number permitted quantitation of HIV-1 copy numbers in the range of 20 to 2,000 copies per micrograms of DNA. Internally controlled PCR (IC-PCR) was based on coamplification of the nef region and the ras gene as an internal endogenous standard. Correlation to known amounts of HIV-1 DNA permitted quantitation by IC-PCR of HIV-1 copy numbers in the range of 10 to 2,000 copies per microgram of DNA. QC- and IC-PCR-ELOSA were performed on a panel of 53 seropositive patients and 12 seronegative controls. The methods showed similar coefficients of variation below 24%. Quantitations by QC- and IC-PCR-ELOSA were identical for 77% of patient samples. The copy level ranged between 443 +/- 156 and 21,453 +/- 13,511 copies per 10(5) CD4 cells for asymptomatic and AIDS patients, respectively. The simplicity and reliability of QC- and IC-PCR-ELOSA methods make them appropriate for routine laboratory use in the quantitation of viral and bacterial DNAs.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8586703      PMCID: PMC228674          DOI: 10.1128/jcm.33.12.3201-3208.1995

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  26 in total

1.  Clinical correlation and genetic polymorphism of the human immunodeficiency virus proviral DNA obtained after polymerase chain reaction amplification.

Authors:  J Genesca; R Y Wang; H J Alter; J W Shih
Journal:  J Infect Dis       Date:  1990-11       Impact factor: 5.226

2.  Quantitation of human immunodeficiency virus DNA by using the polymerase chain reaction.

Authors:  R E Dickover; R M Donovan; E Goldstein; S Dandekar; C E Bush; J R Carlson
Journal:  J Clin Microbiol       Date:  1990-09       Impact factor: 5.948

3.  Use of competitive polymerase chain reaction to determine HIV-1 levels in response to antiviral treatments.

Authors:  S M Bruisten; M H Koppelman; M T Roos; A E Loeliger; P Reiss; C A Boucher; H G Huisman
Journal:  AIDS       Date:  1993-11       Impact factor: 4.177

4.  Quantitative analysis of HIV-1 proviral DNA in peripheral blood mononuclear cells from patients with AIDS or ARC: decrease of proviral DNA content following treatment with 2',3'-dideoxyinosine (ddI).

Authors:  S Aoki; R Yarchoan; R V Thomas; J M Pluda; K Marczyk; S Broder; H Mitsuya
Journal:  AIDS Res Hum Retroviruses       Date:  1990-11       Impact factor: 2.205

5.  Quantitation of human immunodeficiency virus provirus and circulating virus: relationship with immunologic parameters.

Authors:  S Yerly; E Chamot; B Hirschel; L H Perrin
Journal:  J Infect Dis       Date:  1992-08       Impact factor: 5.226

6.  Human immunodeficiency virus-infected individuals contain provirus in small numbers of peripheral mononuclear cells and at low copy numbers.

Authors:  P Simmonds; P Balfe; J F Peutherer; C A Ludlam; J O Bishop; A J Brown
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

7.  Quantitative assessment of HIV-1 DNA load by coamplification of HIV-1 gag and HLA-DQ-alpha genes.

Authors:  T H Lee; F J Sunzeri; L H Tobler; B G Williams; M P Busch
Journal:  AIDS       Date:  1991-06       Impact factor: 4.177

8.  Quantitation of HIV-1 proviral DNA relative to cellular DNA by the polymerase chain reaction.

Authors:  D E Kellogg; J J Sninsky; S Kwok
Journal:  Anal Biochem       Date:  1990-09       Impact factor: 3.365

9.  HIV-1 in blood monocytes: frequency of detection of proviral DNA using PCR and comparison with the total CD4 count.

Authors:  P Innocenti; M Ottmann; P Morand; P Leclercq; J M Seigneurin
Journal:  AIDS Res Hum Retroviruses       Date:  1992-02       Impact factor: 2.205

10.  A comparison of non-radioisotopic hybridization assay methods using fluorescent, chemiluminescent and enzyme labeled synthetic oligodeoxyribonucleotide probes.

Authors:  M S Urdea; B D Warner; J A Running; M Stempien; J Clyne; T Horn
Journal:  Nucleic Acids Res       Date:  1988-06-10       Impact factor: 16.971

View more
  5 in total

Review 1.  Comparison of competitive and positive control-based PCR quantitative procedures coupled with end point detection.

Authors:  F Mallet
Journal:  Mol Biotechnol       Date:  2000-03       Impact factor: 2.695

2.  Comparative study of different standardization concepts in quantitative competitive reverse transcription-PCR assays.

Authors:  G Haberhausen; J Pinsl; C C Kuhn; C Markert-Hahn
Journal:  J Clin Microbiol       Date:  1998-03       Impact factor: 5.948

3.  Quantitation of human immunodeficiency virus type 1 DNA forms with the second template switch in peripheral blood cells predicts disease progression independently of plasma RNA load.

Authors:  Leondios G Kostrikis; Giota Touloumi; Rose Karanicolas; Nikos Pantazis; Cleo Anastassopoulou; Anastasia Karafoulidou; James J Goedert; Angelos Hatzakis
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

4.  Clinical evaluation of an in-house reverse transcription-competitive PCR for quantitation of human immunodeficiency virus type 1 RNA in plasma.

Authors:  M Zazzi; L Romano; M Catucci; G Venturi; A De Milito; P E Valensin
Journal:  J Clin Microbiol       Date:  1999-02       Impact factor: 5.948

5.  A quantitative polymerase chain reaction-enzyme immunoassay for accurate measurements of human papillomavirus type 16 DNA levels in cervical scrapings.

Authors:  M V Jacobs; J M Walboomers; J van Beek; F J Voorhorst; R H Verheijen; C J Meijer; A J van den Brule; T J Helmerhorst; P J Snijders
Journal:  Br J Cancer       Date:  1999-09       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.